Redx announced that its Board of Directors has established a Science Committee. The Science Committee will be responsible for reviewing and assessing Redx's R&D programs and strategies, in addition to overseeing the Company's progress in achieving its R&D goals and objectives. The new Committee will be chaired by Dr. Bernhard Kirschbaum, a longstanding member of the Board with over 25 years of experience in pharmaceutical research and drug development.

The Committee will also consist of Chief Executive Officer, Lisa Anson and Non-Executive Director, Dr. Rob Scott as members. As a result of his new responsibilities, Dr. Kirschbaum will step down from his role as Chair of the Remuneration Committee, but will remain a member of this committee. The Board has appointed Sarah Gordon Wild as the new Chair of the Remuneration Committee.

Sarah has extensive experience in the biotechnology sector and capital markets, including over 20 years as a senior biotechnology/healthcare analyst on Wall Street. Dr. Kirschbaum will also step down from his role as a committee member on the Audit Committee, and will be replaced by Dr. Rob Scott. The changes are all effective immediately.